Spatial competition constrains resistance to targeted cancer therapy
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Spatial competition constrains resistance to targeted cancer therapy
Authors
Keywords
-
Journal
Nature Communications
Volume 8, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-12-04
DOI
10.1038/s41467-017-01516-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- How to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient
- (2017) Elsa Hansen et al. PLOS BIOLOGY
- Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution
- (2016) Boyang Zhao et al. CELL
- Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution
- (2015) Nicholas McGranahan et al. CANCER CELL
- Improving Cancer Treatment via Mathematical Modeling: Surmounting the Challenges Is Worth the Effort
- (2015) Franziska Michor et al. CELL
- Targeting cancer with kinase inhibitors
- (2015) Stefan Gross et al. JOURNAL OF CLINICAL INVESTIGATION
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- FDA-approved small-molecule kinase inhibitors
- (2015) Peng Wu et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Targeting CDK4 and CDK6: From Discovery to Therapy
- (2015) C. J. Sherr et al. Cancer Discovery
- Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS
- (2015) Barbie Taylor-Harding et al. Oncotarget
- CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
- (2014) A. DeMichele et al. CLINICAL CANCER RESEARCH
- The Model Muddle: In Search of Tumor Growth Laws
- (2013) P. Gerlee CANCER RESEARCH
- The Proliferation-Quiescence Decision Is Controlled by a Bifurcation in CDK2 Activity at Mitotic Exit
- (2013) Sabrina L. Spencer et al. CELL
- Evolutionary dynamics of cancer in response to targeted combination therapy
- (2013) Ivana Bozic et al. eLife
- Evolutionary Approaches to Prolong Progression-Free Survival in Breast Cancer
- (2012) A. S. Silva et al. CANCER RESEARCH
- Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors
- (2012) Jeffry L. Dean et al. CELL CYCLE
- An Integrated Chemical Biology Approach Provides Insight into Cdk2 Functional Redundancy and Inhibitor Sensitivity
- (2012) Aude Echalier et al. CHEMISTRY & BIOLOGY
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- Chemical-genetic analysis of cyclin dependent kinase 2 function reveals an important role in cellular transformation by multiple oncogenic pathways
- (2012) D. Horiuchi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cyclin-dependent kinase 1 (Cdk1) is essential for cell division and suppression of DNA re-replication but not for liver regeneration
- (2012) M. K. Diril et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer
- (2011) Gottfried E. Konecny et al. CLINICAL CANCER RESEARCH
- Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301
- (2011) Huw D. Thomas et al. EUROPEAN JOURNAL OF CANCER
- The CDK inhibitors in cancer research and therapy
- (2011) Jonas Cicenas et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Switching Cdk2 On or Off with Small Molecules to Reveal Requirements in Human Cell Proliferation
- (2011) Karl A. Merrick et al. MOLECULAR CELL
- A theoretical quantitative model for evolution of cancer chemotherapy resistance
- (2010) Ariosto S Silva et al. Biology Direct
- On measuring selection in experimental evolution
- (2010) L.-M. Chevin Biology Letters
- Selective chemical inhibition as a tool to study Cdk1 and Cdk2 functions in the cell cycle
- (2010) Liliana Krasinska et al. CELL CYCLE
- Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
- (2010) W. R. Wiedemeyer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Adaptive Therapy
- (2009) R. A. Gatenby et al. CANCER RESEARCH
- A change of strategy in the war on cancer
- (2009) Robert A. Gatenby NATURE
- Cdk2 suppresses cellular senescence induced by the c-myc oncogene
- (2009) Stefano Campaner et al. NATURE CELL BIOLOGY
- Spheroid-based drug screen: considerations and practical approach
- (2009) Juergen Friedrich et al. Nature Protocols
- Molecular Basis of Drug Resistance in Aurora Kinases
- (2008) Fiona Girdler et al. CHEMISTRY & BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now